Title:
CARBONIC ANHYDRASE 1 (CA1) INHIBITORS FOR THE TREATMENT OR PREVENTION OF MYELOPROLIFERATIVE DISORDERS AND OTHER HEMATOPOIETIC MALIGNANCIES, AND AS BIOMARKER OF MYELOPROLIFERATIVE DISORDERS AND OTHER HEMATOPOIETIC MALIGNANCIES
Document Type and Number:
WIPO Patent Application WO/2022/200613
Kind Code:
A3
Abstract:
The invention relates to the treatment or prevention of myeloproliferative disorders and other hematopoietic malignancies. Herein is described a carbonic Anhydrase 1 (CA1) inhibitor; for use in a method for treating or preventing a myeloproliferative disorder, an acute myeloid leukemia (AML) and/or a primary or secondary myelofibrosis. Herein is further described the use of carbonic Anhydrase 1 as a biomarker for myeloproliferative disorders and other hematopoietic malignancies; and/or as a biomarker of the efficacy of compounds for treating or preventing said conditions.
Inventors:
ROMEO PAUL-HENRI (FR)
LEWANDOWSKI DANIEL (FR)
BARROCA VILMA (FR)
MURAKAMI SHOHEI (FR)
LEWANDOWSKI DANIEL (FR)
BARROCA VILMA (FR)
MURAKAMI SHOHEI (FR)
Application Number:
PCT/EP2022/058009
Publication Date:
November 17, 2022
Filing Date:
March 25, 2022
Export Citation:
Assignee:
COMMISSARIAT ENERGIE ATOMIQUE (FR)
INST NAT SANTE RECH MED (FR)
UNIV PARIS CITE (FR)
UNIV PARIS SACLAY (FR)
INST NAT SANTE RECH MED (FR)
UNIV PARIS CITE (FR)
UNIV PARIS SACLAY (FR)
International Classes:
A61K31/341; A61K31/433; A61K45/06; A61P35/00; G01N33/50
Other References:
ASSI RITA ET AL: "Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome : Indisulam With Idarubicin & Ara-C in AML", vol. 124, no. 13, 16 April 2018 (2018-04-16), US, pages 2758 - 2765, XP055831911, ISSN: 0008-543X, Retrieved from the Internet [retrieved on 20210826], DOI: 10.1002/cncr.31398
FRANCESCO ABBATE ET AL: "Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, no. 1, 1 January 2004 (2004-01-01), pages 217 - 223, XP055150601, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2003.09.062
SUPURAN C T ET AL: "Carbonic anhydrase inhibitors - Part 94. 1,3,4-Thiadiazole-2-sulfonamide derivatives as antitumor agents?^#", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 35, no. 9, 1 September 2000 (2000-09-01), pages 867 - 874, XP004331220, ISSN: 0223-5234, DOI: 10.1016/S0223-5234(00)00169-0
LUCHETTI FRANCESCA ET AL: "The K562 chronic myeloid leukemia cell line undergoes apoptosis in responseto interferon-alpha", HAEMATOLOGICA 1998; 83: 974-980, 1 January 1998 (1998-01-01), XP055835409, Retrieved from the Internet [retrieved on 20210826]
FRANCESCO ABBATE ET AL: "Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, no. 1, 1 January 2004 (2004-01-01), pages 217 - 223, XP055150601, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2003.09.062
SUPURAN C T ET AL: "Carbonic anhydrase inhibitors - Part 94. 1,3,4-Thiadiazole-2-sulfonamide derivatives as antitumor agents?^#", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 35, no. 9, 1 September 2000 (2000-09-01), pages 867 - 874, XP004331220, ISSN: 0223-5234, DOI: 10.1016/S0223-5234(00)00169-0
LUCHETTI FRANCESCA ET AL: "The K562 chronic myeloid leukemia cell line undergoes apoptosis in responseto interferon-alpha", HAEMATOLOGICA 1998; 83: 974-980, 1 January 1998 (1998-01-01), XP055835409, Retrieved from the Internet
Attorney, Agent or Firm:
CABINET NONY (FR)
Download PDF:
Previous Patent: SYSTEM AND METHOD FOR INTERACTIVE VIRTUAL CYCLING
Next Patent: MEAT MINCING APPARATUS AND MEAT MINCING ACCESSORY
Next Patent: MEAT MINCING APPARATUS AND MEAT MINCING ACCESSORY